US Senate pace slows on user fee bill
This article was originally published in Clinica
Executive Summary
Sometimes the only train running is the slow one. The US Senate began debate April 30 on a bill designed primarily to reauthorise laws that request prescription drug and medical device companies to pay the Food and Drug Administration (FDA) user fees in exchange for speedier product reviews. However, since the bill is likely to represent the only chance that members of Congress will get to address a whole host of other regulatory issues governed by the Food, Drug and Cosmetic Act, many members want to make their mark on issues that are only tangentially related.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.